The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine

Journal of Psychopharmacology

Volumn 21, Issue 6, 2007, Pages 650-656

  Yoshida, Keizo ^a   Higuchi, Hisashi ^b   Kamata, Mitsuhiro ^c   Takahashi, Hitoshi ^d   Inoue, Kazuyuki ^e   Suzuki, Toshio ^e   Itoh, Kunihiko ^f   Ozaki, Norio ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Omagari City Hospital   (Japan)

^c Yuri Kumiai General Hospital   (Japan)

^d Yokote Public Hospital   (Japan)

^e AKITA UNIVERSITY HOSPITAL   (Japan)

^f UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

Antidepressant effect; Fluvoxamine; Genetic polymorphism; Major depressive disorder; Milnacipran

Indexed keywords

BENZODIAZEPINE; BRAIN DERIVED NEUROTROPHIC FACTOR; BROTIZOLAM; FLUVOXAMINE; MILNACIPRAN;

ADULT; AGED; ALLELE; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DATA ANALYSIS; DEPRESSION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK REDUCTION; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIDEPRESSIVE AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CYCLOPROPANES; DEPRESSION; EXONS; FEMALE; FLUVOXAMINE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT SELECTION; PHENOTYPE; POLYMORPHISM, GENETIC; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 34249317809     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881106072192     Document Type: Article

References (30)

1. Buchner A., Faul F., Erdfelder E. (1996) G.Power: A priori, post-hoc, and compromise power analyses for the Macintosh (Version 2.1.1) [Computer program]. University of Trier, Trier, Germany
2. Burke M.J., Preskorn S.H. (1999) Therapeutic drug monitoring of antidepressants: cost implications and relevance to clinical practice. Clin Pharmacokinet 37: 147 - 165
3. Campbell S., Macqueen G. (2004) The role of the hippocampus in the pathophysiology of major depression. J Psychiatry Neurosci 29: 417 - 426
4. Charlier C., Pinto E., Ansseau M., Plomteux G. (2002) Venlafaxine: the relationship between dose, plasma concentration and clinical response in depressive patients. J Psychopharmacol 16: 369 - 372
5. Comings D.E., MacMurray J.P. (2000) Molecular heterosis: a review. Mol Genet Metab 71: 19 - 31
6. Czeh B., Michaelis T., Watanabe T., Frahm J., de Biurrun G., van Kampen M., Bartolomucci A., Fuchs E. (2001) Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc Natl Acad Sci U S A 98: 12796 - 12801
7. Dagher A., Owen A.M., Boecker H., Brooks D.J. (1999) Mapping the network for planning: a correlational PET activation study with the Tower of London task. Brain 122 (Pt 10). 1973 - 1987
8. Drevets W.C. (1999) Prefrontal cortical-amygdalar metabolism in major depression. Ann N Y Acad Sci 877: 614 - 637
9. Egan M.F., Kojima M., Callicott J.H., Goldberg T.E., Kolachana B.S., Bertolino A., Zaitsev E., Gold B., Goldman D., Dean M., Lu B., Weinberger D.R. (2003) The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112: 257 - 269
10. Foltynie T., Lewis S.G., Goldberg T.E., Blackwell A.D., Kolachana B.S., Weinberger D.R., Robbins T.W., Barker R.A. (2005) The BDNF Val66Met polymorphism has a gender specific influence on planning ability in Parkinson's disease. J Neurol 252: 833 - 838
11. Hawley C.J., Gale T.M., Sivakumaran T. (2002) Defining remission by cut off score on the MADRS: selecting the optimal value. J Affect Disord 72: 177 - 184
12. Higuchi H., Yoshida K., Takahashi H., Naito S., Kamata M., Ito K., Sato K., Tsukamoto K., Shimizu T., Nakanishi M., Hishikawa Y. (2003) Milnacipran plasma levels and antidepressant response in Japanese major depressive patients. Hum Psychopharmacol 18: 255 - 259
13. Hong C.J., Huo S.J., Yen F.C., Tung C.L., Pan G.M., Tsai S.J. (2003) Association study of a brain-derived neurotrophic-factor genetic polymorphism and mood disorders, age of onset and suicidal behavior. Neuropsychobiology 48: 186 - 189
14. Kunugi H., Ueki A., Otsuka M., Isse K., Hirasawa H., Kato N., Nabika T., Kobayashi S., Nanko S. (2001) A novel polymorphism of the brain-derived neurotrophic factor (BDNF) gene associated with late-onset Alzheimer's disease. Mol Psychiatry 6: 83 - 86
15. Malhotra A.K., Murphy G.M. Jr, Kennedy J.L. (2004) Pharmacogenetics of psychotropic drug response. Am J Psychiatry 161: 780 - 796
16. Momose Y., Murata M., Kobayashi K., Tachikawa M., Nakabayashi Y., Kanazawa I., Toda T. (2002) Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms. Ann Neurol 51: 133 - 136
17. Montgomery S.A., Åsberg M. (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382 - 389
18. Nakata K., Ujike H., Sakai A., Uchida N., Nomura A., Imamura T., Katsu T., Tanaka Y., Hamamura T., Kuroda S. (2003) Association study of the brain-derived neurotrophic factor (BDNF) gene with bipolar disorder. Neurosci Lett 337: 17 - 20
19. Ohkubo T., Shimoyama R., Otani K., Yoshida K., Higuchi H., Shimizu T. (2003) High-performance liquid chromatographic determination of fluvoxamine and fluvoxamino acid in human plasma. Anal Sci 19: 859 - 864
20. Okamoto H., Shino Y., Hashimoto K., Kumakiri C., Shimizu E., Shirasawa H., Iyo M. (2003) Dynamic changes in AP-1 transcription factor DNA binding activity in rat brain following administration of antidepressant amitriptyline and brain-derived neurotrophic factor. Neuropharmacology 45: 251 - 259
21. Perry P.J., Pfohl B.M., Holstad S.G. (1987) The relationship between antidepressant response and tricyclic antidepressant plasma concentrations. A retrospective analysis of the literature using logistic regression analysis. Clin Pharmacokinet 13: 381 - 392
22. Robbins T.W. (1996) Dissociating executive functions of the prefrontal cortex. Philos Trans R Soc Lond B Biol Sci 351: 1463 - 1470 ; discussion 1470 - 1471
23. Russo-Neustadt A., Beard R.C., Cotman C.W. (1999) Exercise, antidepressant medications, and enhanced brain derived neurotrophic factor expression. Neuropsychopharmacology 21: 679 - 682
24. Shirayama Y., Chen A.C., Nakagawa S., Russell D.S., Duman R.S. (2002) Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 22: 3251 - 3261
25. Smith M.A., Makino S., Kvetnansky R., Post R.M. (1995) Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J Neurosci 15: 1768 - 1777
26. Stahl S.M. (2000) Blue genes and the monoamine hypothesis of depression. J Clin Psychiatry 61: 77 - 78
27. Szekeres G., Juhasz A., Rimanoczy A., Keri S., Janka Z. (2003) The C270T polymorphism of the brain-derived neurotrophic factor gene is associated with schizophrenia. Schizophr Res 65: 15 - 18
28. Tsai S.J., Cheng C.Y., Yu Y.W., Chen T.J., Hong C.J. (2003) Association study of a brain-derived neurotrophic-factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response. Am J Med Genet B Neuropsychiatr Genet 123: 19 - 22
29. Yoshida K., Takahashi H., Higuchi H., Kamata M., Ito K., Sato K., Naito S., Shimizu T., Itoh K., Inoue K., Suzuki T., Nemeroff C.B. (2004) Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am J Psychiatry 161: 1575 - 1580
30. Yoshida K., Ito K., Sato K., Takahashi H., Kamata M., Higuchi H., Shimizu T., Itoh K., Inoue K., Tezuka T., Suzuki T., Ohkubo T., Sugawara K., Otani K. (2002) Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 26: 383 - 386